A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people lose weight.

Recruiting now. Registry record last updated October 8, 2025.

Who can join: Adults 18 to 65, have obesity, BMI 30+.
What you take: cagrisema, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 2.1 years; your own time in it is usually shorter.
What you get: Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 1Sponsor Novo Nordisk A/SDrug cagrisemaClass OtherSites 2 USEnrollment target 80

What this study is for

Primary condition: Obesity.

Full scientific study title: A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet.

Who can join

Age18 to 65SexAnyBMI30 or higher

Adults 18 to 65, have obesity, BMI 30+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Male or female (sex assigned at birth).
Age 18-65 years (both inclusive) at the time of signing the informed consent.
Body Mass Index (BMI) greater than or equal to (≥) 30.0 kilograms per square meter (kg/m\^2) at screening (Visit 1). Excess body weight should be due to excess adipose tissue, as judged by the investigator.

Key exclusion criteria

Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive method.
History of diabetes mellitus of any type, other than gestational diabetes mellitus.
Claustrophobia or severe discomfort of being confined in small rooms.
Contraindication for magnetic resonance imaging (MRI) scanning as per local guidance, including physical limitations that prevent the MRI scan.
Unusual meal habits (including, but not limited to, eating disorders) and special diet requirements or unwillingness to eat the food provided in the study.

Where this trial is enrolling

This trial has 2 sites across 2 states. Contact a site coordinator directly to start screening.

Find a site near you

Florida1 site

Advent Health-Res Inst
Orlando, Florida

Louisiana1 site

Pennington Biomed Res Ctr
Baton Rouge, Louisiana

Follow this trial

We email you if NCT07184086 changes status, adds new sites in your state, or if a similar trial opens for the same condition. No spam, opt out any time.

Timeline

Started enrolling: September 26, 2025. Expected completion: October 12, 2027. Last updated on ClinicalTrials.gov: October 8, 2025.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.